GLP-1 Drugs

GLP-1 receptor agonists mimic a natural hormone in the body to help regulate blood sugar and minimize certain cravings. Originally developed to treat diabetes, these drugs are now regularly used for weight loss. They have also been linked to significant reductions in certain cardiovascular outcomes, including heart attack and stroke.

These drugs represent one of modern healthcare’s biggest trends. Two popular injectable examples are semaglutide, sold by Novo Nordisk under the brand names Wegovy and Ozempic, and tirzepatide, a dual GIP/GLP-1 receptor agonist sold by Eli Lilly and Company under the brand names Zepbound and Mounjaro. For patients hoping to avoid injections, there are also a semaglutide pill from Novo Nordisk and orforglipron, a GLP-1 pill from Eli Lilly and Company.

GLP-1 drugs outperform metformin in patients with prediabetes
Metformin is typically the therapy of choice for patients with prediabetes, but GLP-1 drugs appear to offer several benefits.
A big win for Foundayo: GLP-1 pill orforglipron helps patients lose weight, protect their hearts
Orforglipron was linked to consistent weight loss in addition to reductions in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol and high-sensitivity C-reactive protein. In terms of safety, it was found to be noninferior to insulin glargine.
More and more young children now taking GLP-1 drugs for weight loss
Some parents may be unsure about giving their children these medications. However, it can be worth it to avoid a lifetime of high blood pressure and other potentially harmful health conditions.
Should patients on semaglutide increase their dose or try tirzepatide? A real-world look at cardiovascular outcomes
A new analysis found that one approach may outperform the other when it comes to minimizing the patient's risk of major cardiovascular events.
Semaglutide is improving the heart health of millions—but how? Experts are stumped
“Our analyses could not fully ascribe the effects of semaglutide on cardiovascular disease to known risk factors with any certainty,” one researcher said after exploring years of data. "These results suggest that semaglutide should be considered as a cardiovascular disease reduction drug and not just as a weight loss drug."

GLP-1 drugs outperform metformin in patients with prediabetes

Metformin is typically the therapy of choice for patients with prediabetes, but GLP-1 drugs appear to offer several benefits.

doctor with overweight patient who may be treated with TAVR or surgery

A big win for Foundayo: GLP-1 pill orforglipron helps patients lose weight, protect their hearts

Orforglipron was linked to consistent weight loss in addition to reductions in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol and high-sensitivity C-reactive protein. In terms of safety, it was found to be noninferior to insulin glargine.

weight loss scale overweight obese lose weight pounds

More and more young children now taking GLP-1 drugs for weight loss

Some parents may be unsure about giving their children these medications. However, it can be worth it to avoid a lifetime of high blood pressure and other potentially harmful health conditions.

Should patients on semaglutide increase their dose or try tirzepatide? A real-world look at cardiovascular outcomes

A new analysis found that one approach may outperform the other when it comes to minimizing the patient's risk of major cardiovascular events.

obesity semaglutide tirzepatide GLP-1 drugs weight loss

Semaglutide is improving the heart health of millions—but how? Experts are stumped

“Our analyses could not fully ascribe the effects of semaglutide on cardiovascular disease to known risk factors with any certainty,” one researcher said after exploring years of data. "These results suggest that semaglutide should be considered as a cardiovascular disease reduction drug and not just as a weight loss drug."

Tirzepatide, a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1), has been approved by the U.S. Food & Drug Administration (FDA) for improving glycemic control among adults with type 2 diabetes. The medication, sold by Eli Lilly and Company under the name Mounjaro, will be available in six different doses and come in an auto-injector pen.

FDA approves tirzepatide for reducing cardiovascular risk in adults with type 2 diabetes

The popular diabetes drug, sold by Eli Lilly and Company under the brand name Mounjaro, has been at the center of many cardiology trials over the years. It is the first dual GIP and GLP-1 hormone receptor agonist approved by the FDA for this indication.

Tirzepatide linked to better outcomes for heart patients with type 2 diabetes

The study's authors reviewed data from more than 50,000 patients, confirming that patients given tirzepatide were less likely to die or experience a heart attack than those given an older diabetes medication.

Novo Nordisk sues GLP-1 rival Eli Lilly over claims of false advertising

Novo Nordisk filed a lawsuit claiming Eli Lilly ran “false and materially misleading” advertisements that ignore recent data. According to Lilly, though, its message is "truthful" and "grounded in the most direct scientific evidence available."

Around the web

Radiology Business

Shielding system linked to lower operator radiation exposure during IR procedures

Health Exec

An inside look at the changing culture of the FDA